%0 Journal Article
%T Erratum
%A Barrese V
%A Miceli F
%A Soldovieri MV
%A Ambrosino P
%J Clinical Pharmacology: Advances and Applications
%D 2012
%I Dove Medical Press
%X Barrese V, Miceli F, Soldovieri MV, Ambrosino P, Iannotti FA, Cilio MR, Taglialatela M. Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine. Clinical Pharmacology: Advances and Applications. 2010;2:225¨C236.On page 233, left-hand column, second paragraph, line 17 forward, it says:¡°The most common reasons for discontinuation were dizziness, confusion, somnolence, and asthenia, with the highest proportion of withdrawals in patients receiving retigabine 1200 mg/kg.72 In RESTORE 1, where retigabine was used at 1200 mg/kg, urinary or renal disorders were observed in 12% of patients.¡±In this passage, both instances of ¡°retigabine 1200 mg/kg¡± should be ¡°retigabine 1200 mg/day.¡±Read original article
%U http://www.dovepress.com/erratum-neuronal-potassium-channel-a9568